Gene study could make malaria pills work better
NCT ID NCT07373743
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This early-phase study looks at how different genetic backgrounds change the way healthy adults process tafenoquine, a drug used to prevent malaria. About 20 participants aged 18-65 will give blood and urine samples to measure drug levels. The goal is to improve dosing for future travelers to malaria-prone areas.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC IN NORMAL POPULATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SUNY Upstate Medical University, Upstate Global Health Institute
East Syracuse, New York, 13057, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.